Related Experiment Video
Updated: Jul 31, 2025
A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
Published on: March 3, 2023
Rifampicin in periprosthetic joint infections: where do we stand and where are we headed?
Marjan Wouthuyzen-Bakker1, Henk Scheper2
1Department of medical microbiology and infection prevention, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Introduction:
A periprosthetic joint infection (PJI) is a major complication of arthroplasty. Treatment of PJI consists of surgical debridement with or without the exchange of the implant and long-term antimicrobial treatment. Rifampicin is regarded as one of the cornerstones of antimicrobial treatment for staphylococcal PJI, but the exact role of rifampicin for PJI in different clinical scenarios remains to be elucidated.
Areas Covered:
In this perspective article, an overview is provided of in vitro, in vivo and clinical studies that were the basis of the current guidelines and recommendations for rifampicin use in daily practice for PJI. Controversial issues on indication, dosing, timing, duration, and antibiotic drug interactions will be addressed. Finally, the most urgent clinical questions on rifampicin use that need answering in the nearby future will be formulated.
Expert Opinion:
Many inquiries remain concerning the exact indications and clinical use of rifampicin in PJI. Randomized controlled trials are needed to answer these questions.
Insights
Rifampicin is crucial for treating staphylococcal periprosthetic joint infections (PJI). Further research is needed to clarify its optimal use in various clinical situations for better patient outcomes.
Area of Science:
- Orthopedics
- Infectious Diseases
- Pharmacology
Background:
- Periprosthetic joint infection (PJI) is a significant complication following arthroplasty.
- Current treatment involves surgery and prolonged antimicrobial therapy.
- Rifampicin is a key antibiotic for staphylococcal PJI, but its precise role requires further definition.
Purpose of the Study:
- To provide an overview of studies underpinning current rifampicin guidelines for PJI.
- To address controversial aspects of rifampicin use in PJI management.
- To identify critical unanswered questions for future research.
Main Methods:
- Review of in vitro, in vivo, and clinical studies.
- Analysis of existing guidelines and recommendations.
- Discussion of controversial clinical scenarios.
Main Results:
- Current guidelines and recommendations for rifampicin use in PJI are based on available evidence.
- Several controversial issues regarding rifampicin's indication, dosing, timing, duration, and drug interactions exist.
- Urgent clinical questions regarding rifampicin use in PJI remain.
Conclusions:
- The exact indications and clinical application of rifampicin in PJI management require further elucidation.
- Randomized controlled trials are essential to address the remaining clinical questions.
- Optimizing rifampicin use can improve outcomes for patients with PJI.
More Related Videos
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:18Endocarditis III: Medical Management
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care